Exosomes from Artificial Antigen-Presenting Cells for T Cell Stimulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The generation of sufficient dendritic cell-derived exosomes (DEX) from autologous dendritic cells is a barrier to the wide use of DEX in immunotherapy, and existing artificial antigen-presenting cell (AAPC) technologies, such as latex beads, have limitations in interacting with T cells.
Innovation Solution
The development of exosomes secreted from artificial antigen-presenting cells (aAPCs) that express human leukocyte antigen (HLA) and co-stimulatory molecules like CD32, CD80, CD83, and 4-1BBL, which mimic the function of autologous antigen-presenting cells and stimulate T cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If dendritic cell-derived exosomes (DEX) are used to stimulate T cells, then T cell activation is effective, but sufficient generation of DEX from autologous dendritic cells remains a barrier
Solution Approach 1:
The patent creates artificial antigen-presenting cells (aAPCs) that copy the essential functions of dendritic cells by expressing HLA molecules and co-stimulatory molecules on their surface. These aAPCs can be produced in large quantities and serve as a scalable alternative to autologous dendritic cells, resolving the contradiction between effective T cell activation and sufficient exosome generation.
Solution Approach 2:
The patent modifies the parameters of the antigen-presenting system by using heterologous cells (such as K562 cells) that are transduced to express dendritic cell markers and molecules. This parameter change allows for规模化 production while maintaining the immunostimulatory function needed for effective T cell activation.
2Ease of operation
If latex beads are used as artificial antigen-presenting cells, then precise control of signaling is enabled, but the interaction between T cells and beads differs from natural APCs
Solution Approach 1:
The patent creates composite artificial antigen-presenting cells by combining heterologous cell lines with transduced viral vectors or plasmids that express HLA and co-stimulatory molecules. This composite approach maintains the biological interaction fidelity of natural APCs while enabling precise control over the expressed molecules, thus resolving the contradiction between signaling control and interaction fidelity.
3Duration of action of stationary object
If cellular artificial antigen-presenting cells are used, then long-term access to preparation is provided, but additional enhancement of signaling requires introducing co-stimulatory molecules
Solution Approach 1:
The patent uses universal cell lines such as K562 cells that can be transduced to express various combinations of HLA molecules and co-stimulatory molecules. This universal platform allows for long-term storage and repeated use while enabling flexible modification of signaling capabilities through well-established viral transduction methods, thus resolving the contradiction between long-term accessibility and signaling enhancement complexity.
Data Source
AI summary
The present invention relates to an exosome for stimulating T cells and the pharmaceutical use thereof. Immune exosomes secreted from artificial antigen-presenting cells which express HLA, CD32, and co-stimulatory molecules CD32, CD80, CD83, and 4-1BBL are used to stimulate naive CD8+ T cells whereby preventive and therapeutic effects on tumors, pathogen infections, or autoimmune diseases can be provided.